C hronic heart failure (HF) may lead to irreversible liver injury and cirrhosis. However, the severity of liver injury in patients with HF is difficult to assess, because significant hepatic fibrosis may develop well before abnormal serum liver chemistries or typical findings of portal hypertension are apparent. Furthermore, differentiating irreversible liver injury from transient hepatic congestion due to progressive HF may be challenging because of considerable overlap in the clinical presentation. [1] [2] [3] [4] Most importantly, because hepatic cirrhosis predicts poor clinical outcomes after cardiac surgery, [5] [6] [7] [8] [9] including ventricular assist device (VAD) implantation and cardiac transplant, 10 -15 knowledge of the severity of liver disease in patients with advanced HF has important implications for clinical management.
A detailed histopathologic examination of liver specimens is the gold standard for identification of hepatic fibrosis and cirrhosis. The histopathologic spectrum of liver disease in patients with advanced HF is poorly defined and has not been reviewed in the context of modern pharmacological and device-based therapy. We identified a cohort of patients with advanced HF undergoing evaluation for heart transplant or VAD for whom hepatic pathology (from liver biopsy or autopsy specimens) was available and performed a clinicopathologic correlation with 3 goals: (1) to describe the histopathologic spectrum of liver disease in a contemporary population with advanced HF, (2) to determine the clinical factors associated with severe hepatic fibrosis or cirrhosis, and (3) to describe the clinical implications hepatic fibrosis in severe HF.
Methods

Study Population
We identified all patients who underwent evaluation for VAD or heart transplant at Brigham and Women's Hospital from 1995 to 2006. We cross-referenced this patient group with the Brigham and Women's Hospital Department of Pathology database to identify the subset that had liver pathology specimens obtained during the same time period. Liver tissue was obtained in 1 of 3 ways: (1) transjugular biopsy before transplantation or VAD, (2) wedge biopsy at the time of VAD, or (3) autopsy specimens obtained before or after transplantation or VAD. Demographic and clinical information for patients were obtained through systematic review of the electronic medical record. Clinical data nearest to the date of liver tissue collection were used. A cohort of patients who underwent VAD or transplant evaluation at Brigham and Women's Hospital from 1999 to 2006 who did not have liver pathology available for analysis was used as a reference group. Clinical data for these patients were collected at the time of initial inpatient evaluation.
Percutaneous transjugular liver biopsy is the more common method of assessing hepatic pathology in ambulatory patients with advanced HF before VAD or transplant. Patients undergoing percutaneous transjugular liver biopsy as part of the pretransplant or VAD evaluation were analyzed separately to determine the prevalence of fibrosis in this group and evaluate clinical outcomes including the prevalence of VAD and transplant. Survival at the time of data collection was determined by query of the electronic medical records and the social security death index. The study was approved by the Institutional Review Board at Brigham and Woman's Hospital.
Hepatic Scoring
A single pathologist (J.N.G.), blinded to clinical information, reviewed and scored each specimen for hepatic fibrosis, congestion, hepatocellular necrosis, and vascular features. Liver pathology specimens were graded for hepatic fibrosis using a modification of the Scheuer system for viral hepatitis with the aid of a trichrome stain for collagen. 16 In this system of scoring hepatic fibrosis, grade 0 indicates no fibrosis; grade 1 indicates portal, limited pericentral, or sinusoidal fibrosis; grade 2 indicates periportal, pericentral, and septal fibrosis with no bridging; grade 3 indicates bridging cirrhosis; and grade 4 indicates cirrhosis with complete nodule formation. In dichotomous analyses, grade 0 was considered "no fibrosis," grades 1 to 4 were considered as "fibrosis" with grades 1 to 2 indicating mild fibrosis, and grades 3 to 4 indicating severe fibrosis. Liver biopsies were also scored for congestion, necrosis, and vascular features including loss of central veins, sinusoidal dilation, and portal vein loss using standard criteria. 17 
Statistical Analysis
Student t test and Fisher exact tests were used to compare the study group with the reference cohort. Within the study group, Student t test and 2 tests were used to compare patients with and without hepatic fibrosis. Liver function tests (LFTs) were categorized as normal, inflammatory (isolated increase of alanine aminotransferase and aspartate aminotransferase), obstructive (isolated increase of alkaline phosphatase and total bilirubin), or mixed (increase of alanine aminotransferase, aspartate aminotransferase, total bilirubin, and alkaline phosphatase). Multivariable logistic regression models were built using forward stepwise modeling adjusting for age and gender and including variables that were significant (PϽ0.10) in univariate analyses. Statistical analysis was completed using SPSS version 15 (SPSS Inc., Chicago, Ill). A P value Ͻ0.05 was considered statistically significant.
Results
Characteristics of the Cohort
We identified 61 patients who were evaluated by the Advanced Heart Disease Service at our hospital from 1995 to 2006, who also had liver tissue obtained during the same time period. Pathological specimens were obtained from the transjugular approach during the pretransplant evaluation (nϭ35), at the time of VAD implantation (nϭ8), or at autopsy before or after transplantation or VAD (nϭ18). Tissue was insufficient for analysis in 2 patients. Of the 18 patients with liver tissue obtained at autopsy, 9 patients died before receiving transplantation or VAD and 9 patients received a VAD before death. None of the patients received cardiac transplantation. The mean time from VAD to death was 35Ϯ61 days. The cause of death for the 9 autopsy patients who received a VAD before death was multisystem organ failure (nϭ6), recurrent myocardial infarction due to stent thrombosis (nϭ1), and infection (nϭ1). The cause of death of 1 patient is unknown.
We compared the clinical characteristics of the 59 patients with sufficient liver tissue available for analysis with a cohort of 422 patients undergoing HF evaluation at Brigham and Women's Hospital from 1999 to 2006, who did not have liver tissue obtained during this time period (Table 1 ). Relative to those without hepatic tissue for analysis, subjects with liver tissue had lower serum sodium, higher serum creatinine, bilirubin, and alkaline phosphatase levels, and were more likely to have prior hepatitis C exposure. In addition, subjects with liver tissue had higher right atrial and pulmonary capillary wedge pressures and were more likely to have reduced right ventricular function and moderate or severe tricuspid regurgitation (TR). A similar proportion of patients in both groups went on to receive cardiac transplantation. The higher prevalence of VAD among those with liver tissue reflects the fact that a portion of liver biopsies were obtained at the time of VAD implant.
Liver Histopathology
Of the 59 patients with sufficient tissue for analysis, 47 (79.7%) had evidence of hepatic fibrosis on pathological examination. Of subjects with hepatic fibrosis, 17 (36%) had grade 1 fibrosis, 8 (17%) had grade 2 fibrosis, 13 (28%) had grade 3 fibrosis, and 9 (19%) had grade 4 fibrosis (cirrhosis). Additional histopathologic characteristics of liver tissue are summarized in Table 2 . When stratified by method of liver biopsy, only the presence of sinusoidal fibrosis, a pattern of fibrosis associated with alcohol use, nonalcoholic steatohepatitis, and toxic metabolic injury, differed (Pϭ0.04).
Clinical Factors Associated With Hepatic Fibrosis
The clinical characteristics of patients with and without hepatic fibrosis are presented in Table 3 . Relative to those without hepatic fibrosis, subjects with hepatic fibrosis had worse renal function and were more likely to have moderate or severe TR (odds ratio [OR], 5.0; 95% CI, 1.2 to 21.7) and obstructive or mixed LFT abnormalities (OR, 5.7; 95% CI, 1.4 to 22.3). There was no association between the presence of hepatic fibrosis and gender, age, type of cardiomyopathy, duration of symptoms, prevalence of right or left ventricular dysfunction, cardiac filling pressures, type of biopsy, hepatitis C status, or abnormal abdominal imaging. The sensitivity and specificity of abnormal abdominal imaging for hepatic fibrosis was 30% and 75%, respectively, with a positive Data are meanϮSD or n (%). df indicates degrees of freedom.
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predictive value of 82% and a negative predictive value of 21%. In a multivariable analysis, which included age, gender, creatinine, sodium, pattern of LFT abnormality, and TR, only obstructive or mixed pattern of LFT abnormality was significantly associated with hepatic fibrosis on liver biopsy (OR, 4.8; 95% CI, 1.2 to 19.4). The sensitivity and specificity of obstructive or mixed pattern LFT abnormalities (compared with a normal or inflammatory pattern of LFTs) was 74% and 69%, respectively, with a positive predictive value of 89% and a negative predictive value of 43%. The specificity of abnormal LFTs (obstructive, mixed, or inflammatory) was 66.7%, and the sensitivity was 80%.
Analysis of Transjugular Hepatic Biopsy Specimens
Of the 61 patients identified, 35 (57.4%) had percutaneous transjugular liver biopsies obtained during pre-VAD or transplant evaluation. None of the patients experienced a procedural complication. The distribution of hepatic fibrosis in this subpopulation is shown in Table 4 . Hepatic fibrosis was identified in 26 patients (74%), with 12 patients (34%) having grade 3 or 4 fibrosis. Of the 35 patients who had transjugular liver biopsies, 19 (54.3%) received medical management only, 5 (14.3%) underwent VAD implant alone, 6 (17.1%) underwent VAD followed by heart transplant, and 5 (14.3%) underwent heart transplant only. Patients with no or mild fibrosis (grade 1 or 2) on transjugular liver biopsy were more likely to proceed to VAD and/or heart transplant than patients with bridging fibrosis or cirrhosis (grade 3 or 4) (OR, 7.8; 95% CI, 1.4 to 44.0). In an unadjusted analysis, patients with severe fibrosis were less likely than those with no or mild fibrosis to be alive at the time of data collection (OR, 0.07; 95% CI, 0.01 to 0.42).
Of the 12 patients with grade 3 or 4 fibrosis on transjugular liver biopsy, 1 patient received transplantation and 1 patient received a VAD. The remaining 10 patients were medically treated. The patient who received transplantation had a nonischemic cardiomyopathy attributed to prior chemotherapy. The patient had no history of hepatitis B or C and no history of excessive drinking. The patient's alanine aminotransferase and aspartate aminotransferase were in the normal range. Total bilirubin and alkaline phosphatase were mildly increased at 1.3 (0.3 to 1.2 mg/dL) and 113 (42 to 98 U/L), respectively. The liver was abnormal on abdominal ultrasound, and the patient had moderate TR. The patient died 8 months after transplantation from complications related to posttransplant lymphoproliferative disorder of the gastrointestinal tract.
The patient who received a VAD had restrictive cardiomyopathy attributed to muscular dystrophy. This patient also had no history of hepatitis or excessive alcohol use. Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were within normal limits, although total bilirubin was increased at 2.3 (0.3 to 1.2 mg/dL). The patient had no liver abnormalities detected on abdominal ultrasound and had severe TR. The patient's VAD implant was complicated by substantial bleeding requiring massive blood product transfusion (48 U packed red blood cells, 3 U cryoprecipitate, and 15 U fresh frozen plasma) necessitating delayed sternal closure. The patient passed away Ϸ3 months after VAD implant from sepsis related to an infected sternal wound.
Discussion
We performed a systematic analysis of liver pathology obtained from patients with advanced HF to explore the spectrum of histopathologic abnormalities and their correlation with common clinical markers and outcomes. To our knowledge, this study represents the first description of hepatic histopathologic findings in severe HF since the advent of advanced medical and surgical therapies for chronic HF. We found that hepatic fibrosis is prevalent among patients with advanced HF undergoing liver biopsy, even in the absence of typical clinical, laboratory, or imaging findings of advanced liver disease.
Previous studies have examined the histopathologic findings of liver disease in patients with heart disease. However, these clinicopathologic studies have largely been based on autopsy specimens and involve a broad population of patients with cardiovascular disease. [17] [18] [19] [20] [21] [22] Meyers et al 23 evaluated congestive hepatopathy in a diverse population of patients with acute, chronic, and acute on chronic heart disease by using data obtained from right heart catheterization and transjugular liver biopsy. This study demonstrated a wide range of clinical, hemodynamic, and histological findings of cardiac hepatopathy, which varied based on the chronicity of cardiac disease. Fibrosis severe enough to distort the normal microscopic architecture was identified in 19% of patients. 23 Most patients with advanced HF with liver tissue available for review in our study had liver disease characterized by congestion, pericentral necrosis, pericentral fibrosis, and sinusoidal dilation. Hepatic fibrosis was identified in 79.7% of those evaluated, with grade 3 (bridging fibrosis) or grade 4 fibrosis (cirrhosis) occurring in 37.3% of patients. The high prevalence of fibrosis in our patient population likely reflects the severity of HF in this cohort and the chronicity of disease. In addition to chronic increase in systemic venous pressures, advanced HF is associated with upregulation of proinflammatory cytokines (eg, tumor necrosis factor-␣ and interleukin-1␤) that may contribute to the development of hepatic fibrosis. 24 Oxidative stress may also contribute to disease progression in both heart and liver diseases. 25, 26 The safety and use of liver biopsies from the transjugular approach has been previously evaluated in patients with advanced HF. During a 9-year period in a single institution, 27 Our study confirms and extends these observations regarding the safety of transjugular liver biopsy. Of the 35 patients biopsied by this approach during heart transplant evaluation, all had adequate tissue for scoring of fibrosis, and no acute complications were observed. In nearly every patient, this procedure was combined with right heart catheterization to assess cardiopulmonary hemodynamics. Hepatic venous wedge pressure was not routinely assessed but could have been done if cirrhosis was suspected and confirmatory physiological evidence was needed.
Previous clinical studies have demonstrated that worsening systolic HF and increased severity of TR are associated with worsening LFT abnormalities. 28 Our results amplify these observations and show that moderate to severe TR and an obstructive or mixed pattern of LFT abnormalities are associated with biopsy proven hepatic fibrosis. However, TR may be unreliable as a target for clinical decision making, given that the severity of TR is dependent on dynamic clinical variables including preload, afterload, and left ventricular systolic function. Furthermore, in multivariate analysis, there was no independent association between TR and hepatic fibrosis.
Importantly, many of the clinical characteristics that are typically used to identify liver disease in patients with HF, including physical examination findings and abdominal imaging, had little correlation with hepatic fibrosis in our study. Pretransplantation abdominal imaging in our cohort was done with computed tomography or ultrasound. Imaging tests were obtained at the discretion of the treating physician. This approach yielded an extremely low sensitivity (30%) to detect hepatic fibrosis and a poor negative predictive value (21%). It is possible that scintigraphic liver spleen scans or MRI might have correlated better with the findings on liver biopsy specimens, but this testing was neither conducted on the patients in our sample nor is it a part of routine clinical practice.
Given the low procedural risk and increased diagnostic certainty, transjugular liver biopsy may be the best method to assess hepatic fibrosis in patients with advanced HF before transplantation or VAD. The Figure shows a proposed decision pathway for the role of transjugular liver biopsy in patients with advanced HF.
In addition to providing diagnostic information, our study demonstrates that the presence of hepatic fibrosis on transjugular liver biopsy may provide important prognostic information. Patients with no or mild fibrosis (grade 1 or 2) on transjugular liver biopsy were more likely to undergo VAD and/or heart transplant than patients with severe fibrosis (grade 3 or 4) (OR, 7.8; 95% CI, 1.4 to 44.0). Although the direct contribution of hepatic dysfunction to the outcome is unclear, the 2 patients with severe fibrosis who underwent VAD or transplantation had a particularly complicated postsurgical course. Overall, patients with severe fibrosis were less likely to be alive at the time of data collection (OR, 0.07; 95% CI, 0.01 to 0.42). Accordingly, confirming the presence of hepatic fibrosis seems to be relevant to clinical decision making.
Limitations
The retrospective design of this study and reliance on medical record review are potential limitations. Liver biopsies were not done routinely in all patients with advanced HF at our center; hence, there is inherent selection bias. Comparison of our study population with a cohort of patients with advanced HF in the same institution showed that they were more likely to have previous hepatitis C exposure, had lower serum sodium, and had higher serum creatinine, total bilirubin, and alkaline phosphatase. In addition, subjects with liver tissue for analysis had higher mean right atrial, pulmonary artery, and pulmonary capillary wedge pressures. They were more likely to have abnormal right ventricular function and moderate or severe TR. Accordingly, the prevalence and severity of liver disease in the broader population of patients with advanced HF may be overestimated by this study. In addition, noninvasive hepatic imaging was done at the discretion of the treating physician and scintigraphic liver spleen scans, and MRI was not routinely performed at our center. We did not collect quantitative data on previous alcohol use. Despite these limitations, our study provides important insights into the clinical and pathological spectrum of liver disease in patients with advanced HF.
Conclusions
Hepatic fibrosis was common in our population of patients with advanced HF who had liver tissue available for analysis and may be associated with worse outcomes in this population. Renal dysfunction, significant TR, and abnormal LFTs are associated with hepatic fibrosis, but the predictive value of other clinical features, particularly noninvasive imaging, is limited. A prospective, observational study of transjugular liver biopsy to assess the impact of fibrosis on clinical outcomes after VAD or transplant should be considered.
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